Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Urothelial Cancer × durvalumab × Clear all

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 79 Lung Neoplasms 48 Carcinoma, Hepatocellular 38 Breast Neoplasms 31 Small Cell Lung Carcinoma 28 Squamous Cell Carcinoma of Head and Neck 22 Urinary Bladder Neoplasms 21 Cholangiocarcinoma 21 Colorectal Neoplasms 19 Pancreatic Neoplasms 16 Ovarian Neoplasms 16 Biliary Tract Neoplasms 16 Triple Negative Breast Neoplasms 15 Head and Neck Neoplasms 12 Neoplasm Metastasis 11 Carcinoma, Renal Cell 9 Neoplasms 8 Liver Neoplasms 8 Endometrial Neoplasms 8 Carcinoma, Transitional Cell 8 Esophageal Neoplasms 7 Carcinoma, Squamous Cell 7 Uterine Cervical Neoplasms 6 Prostatic Neoplasms 6 Mesothelioma, Malignant 6 Melanoma 6 Gallbladder Neoplasms 6 Fallopian Tube Neoplasms 6 Adenocarcinoma Of Esophagus 6 Recurrence 5

Interventions

niraparib 1 durvalumab 1 cabozantinib 1 Radiotherapy 1 Everolimus 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02891161 2024-11-27

DUART

Big Ten Cancer Research Consortium

Phase 1/2 Terminated

26 enrolled 20 charts

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡